Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities
New Menu Capability Now Available on VISION and VISION MAX Analyzers Increases Confidence in Blood Transfusion-Related Test Results
ISXM is a serological test used in blood transfusions to detect ABO blood type incompatibility between donor red blood cells and recipient serum/plasma. While electronic crossmatch is becoming more prevalent, many laboratories still perform full crossmatches (AHG/IAT). When a full crossmatch is performed, it is required to also complete an ISXM test.
"We're pleased to continue our legacy and tradition of bringing relevant immunohematology assays to market to further enable transfusion labs to perform critical tests needed for urgent patient care. The availability of ISXM across all Ortho platforms is a direct response to customer requests to improve workflow and respond quickly to patient needs," said
With the addition of ISXM, this new menu capability contributes to Ortho's comprehensive automated testing portfolio. Ortho now has the most comprehensive automated testing portfolio comprised of crossmatching, an antibody panel, titrations and antigen phenotyping. Most laboratories serviced by Ortho perform ISXM manually. With ISXM available on the ORTHO VISION® Platform, not only will laboratory staff now have increased confidence in test results but can shift their focus on value-added tasks and maximizing workflow processes.
The ABO blood group antigens have significant importance in transfusion medicine, as they are the most immunogenic of all the blood group antigens. According to the
For more information about Ortho's automated testing solutions, visit our website.
More than 800,000 patients across the world are impacted by Ortho's tests each day. Because Every Test Is A LifeTM, Ortho provides hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology to ensure test results are fast, accurate and reliable. Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.
From launching the first product to determine Rh+ or Rh- blood type, developing the world's first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first
The company is powered by
Dean L. Blood Groups and Red Cell Antigens [Internet]. Bethesda (MD):
View original content to download multimedia:https://www.prnewswire.com/news-releases/ortho-clinical-diagnostics-announces-launch-of-new-isxm-capabilities-301385025.html
Ortho Media Relations, email@example.com